BVF INC/IL
CIK
1056807
Location
San Francisco, CA
Portfolio Value
Mid
$3,136,560,615
Diversification
Diversified
Filing Date
Global Rank
#895
/ 8,623
▲ 60
· as of Mar 2026
Top Industry
Biotechnology
97.2%
3Y Alpha vs SPY
+4.1%
Period ended 4 months ago
Filed May 15, 2026 · 3mo
25 quarters · since Mar 2020
Clone Performance
Jul 2023–Jul 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Cloned portfolio
+76.2%
SPY
+65.3%
Annualised alpha
+2.6%
Max drawdown
−44.4%
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. It tracks 100% of reported value on average across 13 quarters. Past performance does not predict future results.
Portfolio Concentration
40 tracked positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
14.6%
+0.1 pts
Top 5
44.2%
−1.0 pts
Top 10
62.3%
−1.1 pts
HHI
585
Diversified−10
Portfolio Trend
25 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $3,136,560,615 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
10 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| NKTR | Nektar Therapeutics | +1,000,000 | 2,559,595 | $184,162,860 | |
| GLUE | Monte Rosa Therapeutics, Inc. | +625,000 | 4,460,886 | $73,381,574 | |
| IRON | Disc Medicine, Inc. | +622,312 | 1,272,312 | $81,351,629 | |
| FHTX | Foghorn Therapeutics Inc. | +540,000 | 5,842,000 | $27,924,760 | |
| TCRX | TScan Therapeutics, Inc. | +338,216 | 5,564,290 | $5,619,932 | |
| IMA | ImageneBio, Inc. | +307,900 | 1,110,002 | $5,550,010 | |
| STOK | Stoke Therapeutics, Inc. | +281,883 | 2,547,557 | $82,948,455 | |
| AVTX | Avalo Therapeutics, Inc. | +277,588 | 1,632,845 | $24,378,375 | |
| MIRM | Mirum Pharmaceuticals, Inc. | +89,437 | 1,584,727 | $146,397,080 | |
| PVLA | Palvella Therapeutics, Inc. | +81,980 | 960,989 | $119,787,278 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
11 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| MLTX | MoonLake Immunotherapeutics | −3,750,000 | 16,001,284 | $298,263,933 | |
| FDMT | 4D Molecular Therapeutics, Inc. | −1,750,000 | 2,879,289 | $26,806,180 | |
| RVMD | Revolution Medicines, Inc. | −500,000 | 2,856,782 | $277,822,049 | |
| ANNX | Annexon, Inc. | −429,907 | 8,698,173 | $48,187,878 | |
| SEPN | Septerna, Inc. | −367,533 | 1,353,249 | $32,518,573 | |
| ZYME | Zymeworks Inc. | −204,499 | 3,734,142 | $93,502,915 | |
| IMCR | Immunocore Holdings plc | −194,512 | 1,294,463 | $39,028,059 | |
| GHRS | GH Research PLC | −177,554 | 8,650,158 | $121,621,221 | |
| KURA | Kura Oncology, Inc. | −171,393 | 8,445,769 | $68,664,101 | |
| TYRA | Tyra Biosciences, Inc. | −151,469 | 1,976,196 | $75,688,306 | |
| GPCR | Structure Therapeutics Inc. | −19,664 | 3,459,358 | $166,741,055 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
4 positions
40 tracked positions ·
$3,136,560,615 total
· filing declares
41 positions · $3,139,034,854
· as of Mar 31, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| KYMR |
Kymera Therapeutics, Inc.
Healthcare
|
Held | 5,502,710 | $458,320,715 | 14.61% | |
| MLTX |
MoonLake Immunotherapeutics
Healthcare
|
Reduced | 16,001,284 | $298,263,933 | 9.51% | |
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
Reduced | 2,856,782 | $277,822,049 | 8.86% | |
| NKTR |
Nektar Therapeutics
Healthcare
|
Added | 2,559,595 | $184,162,860 | 5.87% | |
| GPCR |
Structure Therapeutics Inc.
Healthcare
|
Reduced | 3,459,358 | $166,741,055 | 5.32% | |
| MIRM |
Mirum Pharmaceuticals, Inc.
Healthcare
|
Added | 1,584,727 | $146,397,080 | 4.67% | |
| GHRS |
GH Research PLC
Healthcare
|
Reduced | 8,650,158 | $121,621,221 | 3.88% | |
| PVLA |
Palvella Therapeutics, Inc.
Healthcare
|
Added | 960,989 | $119,787,278 | 3.82% | |
| ZYME |
Zymeworks Inc.
Healthcare
|
Reduced | 3,734,142 | $93,502,915 | 2.98% | |
| XNCR |
Xencor Inc
Healthcare
|
Held | 7,133,720 | $86,032,663 | 2.74% | |
| STOK |
Stoke Therapeutics, Inc.
Healthcare
|
Added | 2,547,557 | $82,948,455 | 2.64% | |
| CGEM |
Cullinan Therapeutics, Inc.
Healthcare
|
Held | 5,750,683 | $81,717,205 | 2.61% | |
| IRON |
Disc Medicine, Inc.
Healthcare
|
Added | 1,272,312 | $81,351,629 | 2.59% | |
| XOMA |
XOMA Royalty Corp
Healthcare
|
Held | 2,590,303 | $81,257,805 | 2.59% | |
| OLMA |
Olema Pharmaceuticals, Inc.
Healthcare
|
Held | 5,295,893 | $78,961,764 | 2.52% | |
| TYRA |
Tyra Biosciences, Inc.
Healthcare
|
Reduced | 1,976,196 | $75,688,306 | 2.41% | |
| GLUE |
Monte Rosa Therapeutics, Inc.
Healthcare
|
Added | 4,460,886 | $73,381,574 | 2.34% | |
| ALKS |
Alkermes plc.
Healthcare
|
NEW | 2,000,000 | $70,720,000 | 2.25% | |
| KURA |
Kura Oncology, Inc.
Healthcare
|
Reduced | 8,445,769 | $68,664,101 | 2.19% | |
| ACIU |
AC Immune SA
Healthcare
|
Held | 19,822,436 | $54,511,699 | 1.74% | |
| CBIO |
Crescent Biopharma, Inc.
Healthcare
|
Held | 2,748,763 | $50,494,776 | 1.61% | |
| ANNX |
Annexon, Inc.
Healthcare
|
Reduced | 8,698,173 | $48,187,878 | 1.54% | |
| CMPX |
Compass Therapeutics, Inc.
Healthcare
|
Held | 7,764,842 | $41,076,014 | 1.31% | |
| IMCR |
Immunocore Holdings plc
Healthcare
|
Reduced | 1,294,463 | $39,028,059 | 1.24% | |
| SEPN |
Septerna, Inc.
Healthcare
|
Reduced | 1,353,249 | $32,518,573 | 1.04% | |
| STRO |
Sutro Biopharma, Inc.
Healthcare
|
NEW | 1,251,788 | $31,182,039 | 0.99% | |
| FHTX |
Foghorn Therapeutics Inc.
Healthcare
|
Added | 5,842,000 | $27,924,760 | 0.89% | |
| FDMT |
4D Molecular Therapeutics, Inc.
Healthcare
|
Reduced | 2,879,289 | $26,806,180 | 0.85% | |
| IVVD |
Invivyd, Inc.
Healthcare
|
Held | 19,525,000 | $25,382,500 | 0.81% | |
| AVTX |
Avalo Therapeutics, Inc.
Healthcare
|
Added | 1,632,845 | $24,378,375 | 0.78% | |
| ELDN |
Eledon Pharmaceuticals, Inc.
Healthcare
|
Held | 6,293,282 | $19,383,308 | 0.62% | |
| AVR |
Anteris Technologies Global Corp.
Healthcare
|
NEW | 3,000,000 | $16,650,000 | 0.53% | |
| XFOR |
X4 Pharmaceuticals, Inc
Healthcare
|
Held | 2,233,742 | $9,225,354 | 0.29% | |
| IMUX |
Immunic, Inc.
Healthcare
|
Held | 7,652,972 | $8,494,798 | 0.27% | |
| OKUR |
OnKure Therapeutics, Inc.
Healthcare
|
NEW | 1,978,972 | $8,192,944 | 0.26% | |
| TCRX |
TScan Therapeutics, Inc.
Healthcare
|
Added | 5,564,290 | $5,619,932 | 0.18% | |
| IMA |
ImageneBio, Inc.
Healthcare
|
Added | 1,110,002 | $5,550,010 | 0.18% | |
| TENX |
Tenax Therapeutics, Inc.
Healthcare
|
Held | 339,549 | $5,429,388 | 0.17% | |
| MOLN |
Molecular Partners AG
Healthcare
|
Held | 1,353,968 | $5,373,898 | 0.17% | |
| IVA |
Inventiva S.A.
Healthcare
|
Held | 686,040 | $3,807,522 | 0.12% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.